Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04284202 | PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC | unknown | Phase 2 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Feb 25, 2020 |
| clinicaltrials |
| NCT01405079 | Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation(ADJUVANT) | unknown | Phase 3 | 222 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT04266483 | Cancer Genome Atlas of China:Lung Cancer | unknown | — | 2,500 | Xuanwu Hospital, BeijingOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02725918 | Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure | unknown | Phase 2 | 150 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT04263688 | Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion | unknown | — | 300 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Feb 12, 2020 | clinicaltrials |
| NCT03605602 | A Real World Study Based on NGS (TRUMPRWS)(TRUMPRWS) | unknown | — | 2,700 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03301961 | Multiplex Analysis of Circulating Tumor DNA | unknown | — | 400 | Peking University People's HospitalOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03557411 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04252365 | Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer | unknown | Phase 2 | 20 | Guangdong Association of Clinical TrialsOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT04255836 | Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT01795521 | LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC(LungTech) | unknown | Phase 2 | 39 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 31, 2020 | clinicaltrials |
| NCT04250246 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1(NIBIT-ML1) | unknown | Phase 2 | 184 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT02416739 | Anticancer Activity of Nicotinamide on Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Il Yeong Park, Ph.D.OTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | unknown | Phase 2 | 120 | Hunan Cancer HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04239833 | A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | unknown | Phase 3 | 240 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Jan 27, 2020 | clinicaltrials |
| NCT03827577 | OMEGA, Local Ablative Therapy in Oligometastatic NSCLC(OMEGA) | unknown | Phase 3 | 195 | Azienda Ospedaliera Universitaria Integrata VeronaOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT04229121 | Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients | unknown | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jan 18, 2020 | clinicaltrials |
| NCT03624309 | Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer | unknown | Phase 2 | 84 | Hunan Cancer HospitalOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03741647 | Sleep Apnea and Lung Cancer | unknown | — | 50 | Zagazig UniversityOTHER_GOV | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04213170 | Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04137718 | Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation | unknown | — | 50,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT04211896 | Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer | unknown | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Dec 26, 2019 | clinicaltrials |
| NCT04066335 | Study to Evaluate the Safety of Nanoxel M Inj. | unknown | — | 1,498 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | Dec 18, 2019 | clinicaltrials |
| NCT04199559 | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 16, 2019 | clinicaltrials |
| NCT04193007 | The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC(BRATR) | unknown | Phase 2 | 100 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04182698 | Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC | unknown | Phase 1 / Phase 2 | 90 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04181372 | A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer | unknown | Phase 2 | 50 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04180501 | SRS Sequential Sindilimab in Brain Metastasis of NSLSC | unknown | Phase 2 | 25 | Xiaorong DongOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT04167774 | A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC(Compass-001) | unknown | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04175158 | Clinical Trial in Chinese Healthy Volunteers of GB222 | unknown | Phase 1 | 84 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04164745 | Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer | unknown | Phase 2 | 49 | Peking Union Medical College HospitalOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT04161352 | Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC(R-helper) | unknown | — | 500 | Zhejiang Cancer HospitalOTHER | 0 | Nov 13, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT04153526 | LUCID - LUng Cancer CIrculating Tumour Dna Study(LUCID) | unknown | — | 100 | CCTU- Cancer ThemeOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT04148898 | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis(OWONBNSCLCLM) | unknown | Phase 2 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03910127 | Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | unknown | Phase 1 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04009317 | Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 260 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04056572 | Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | unknown | Phase 2 | 135 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04132102 | To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation | unknown | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT03769805 | Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC(CSOAIMTOAN) | unknown | N/A | 83 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT04133337 | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | unknown | Phase 1 / Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04131543 | Phase II Study With Cabozantinib in Patients With RET Positive NSCLC(CRETA) | unknown | Phase 2 | 25 | University of BolognaOTHER | 1 | Oct 18, 2019 | clinicaltrials |
| NCT04124731 | Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) | unknown | Phase 2 | 98 | Shanghai Chest HospitalOTHER | 0 | Oct 11, 2019 | clinicaltrials |
| NCT04116918 | Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC | unknown | — | 100 | Baodong QinOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT04111913 | A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer | unknown | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT04108013 | A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC | unknown | Phase 2 | 38 | Xuanwu Hospital, BeijingOTHER | 0 | Sep 27, 2019 | clinicaltrials |
| NCT04106180 | SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC | unknown | Phase 2 | 63 | Fudan UniversityOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03396497 | Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | unknown | Phase 1 | 17 | Lycera Corp.INDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT04054531 | Study of KN046 With Chemotherapy in First Line Advanced NSCLC | unknown | Phase 2 | 50 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Feb 25, 2020source: clinicaltrials